- Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
-
Ahn MJ, Han JY, Kim DW, Cho BC, Kang JH, Kim SW, Yang JCH, Mitsudomi , Lee JS
- KMID: 2501220
- Cancer Res Treat.
- 2020 Jan;52(1):284-291.
- doi: 10.4143/crt.2019.200
Purpose Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated... -
- CITED
-
- Close
- SHARE
-
- Close
